Bernstein analyst William Pickering initiated coverage of Roivant Sciences (ROIV) with an Outperform rating and $35 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ROIV:
- Roivant Sciences price target raised to $33 from $31 at JPMorgan
- Midday Fly By: Stocks climb as oil prices pull back
- Video: Moderna advances as settlement seen removing share overhang
- Morning Movers: Moderna rises after entering COVID settlement agreement
- Unlocking Value from IP Settlement and Pipeline Catalysts: Why Roivant Deserves a Buy Rating